Lisata Therapeutics Stock (NASDAQ:LSTA)


FinancialsChartTranscripts

Previous Close

$2.58

52W Range

$2.19 - $3.83

50D Avg

$2.84

200D Avg

$3.03

Market Cap

$21.16M

Avg Vol (3M)

$15.77K

Beta

1.22

Div Yield

-

LSTA Company Profile


Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

25

IPO Date

Mar 01, 1999

Website

LSTA Performance


LSTA Financial Summary


Dec 23Dec 22Dec 21
Revenue-$121.37M-
Operating Income$-25.71M$-57.60M$-29.05M
Net Income$-20.84M$-54.23M$-27.47M
EBITDA$-25.52M$-58.58M$-29.15M
Basic EPS$-2.58$-10.47$-7.45
Diluted EPS$-2.58$-10.47$-7.45

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 12, 24 | 10:07 PM
Q2 24Aug 13, 24 | 12:20 AM
Q1 24May 09, 24 | 12:00 AM

Peer Comparison


TickerCompany
IMNNImunon, Inc.
ANTXAN2 Therapeutics, Inc.
PULMPulmatrix, Inc.
BPTHBio-Path Holdings, Inc.
LIXTLixte Biotechnology Holdings, Inc.
GLUEMonte Rosa Therapeutics, Inc.
RZLTRezolute, Inc.
CADLCandel Therapeutics, Inc.
TPSTTempest Therapeutics, Inc.
PTIXProtagenic Therapeutics, Inc.
MBRXMoleculin Biotech, Inc.